JHM’s recombinant human collagen products are unlocking transformative potential across various fields. In serious medicine, they pave the way for breakthroughs in tissue engineering, tissue repair and regenerative medicine. In consumptive medicine, these innovative products are poised to revolutionize subcutaneous tissue filling and skin anti-aging solutions.

JHM has secured the Class II Medical Device Registration Certificate for its recombinant human collagen repair solution. Registration for additional Class II products is underway.
Class III medical devices are advancing through the preclinical research phase, underscoring JHM’s commitment to innovation and medical excellence.

The current market is dominated by animal-derived collagen, recombinant humanized collagen and recombinant collagen-like proteins. However, JHM’s recombinant human collagen stands apart, delivering unmatched scalability, low immunogenicity, zero virality risks and exceptional purity. These qualities make it a frontrunner in both serious medicine (e.g., artificial blood vessels and bone repair scaffolds) and consumptive medicine (e.g., dermal fillers and anti-aging skin treatments).

According to Frost & Sullivan, the Chinese recombinant collagen market is forecasted to grow at an extraordinary annual compound growth rate of 50% from 2022 to 2027. By 2027, the market value is projected to exceed CN¥54.7 billion, signaling vast opportunities for innovation and expansion.